ESTA Stock Forecast & Price Target

Establishment Labs Hldgs is viewed favorably because Motiva is showing clear share-gain momentum in the U.S. and abroad, with survey data indicating U.S. adoption tracking around ~23% as of 2Q26, 58% of respondents actively using Motiva, and expectations rising to 37% in 2027, while established markets already demonstrate 40%+ share that supports the case for broader penetration. The company is also translating that adoption into strong operating performance, delivering Q1 revenue of $59.9M (+45% y/y) and Q2 revenue of $67.5M (+32% y/y), alongside three and four consecutive quarters of positive adjusted EBITDA, with 2026 revenue guidance raised to $266.5M-$268.5M and gross margin guidance of 71.2%-72.2%. Beyond core implants, the minimally invasive platform and Preservé are emerging as meaningful incremental growth drivers, generating $9.1M in Q1 and $12.1M in Q2 across more than 40 markets, while the pipeline for reconstruction and other product expansions adds additional long-term upside and supports the expectation of free cash flow positivity in the second half of 2026.

Establishment Labs Hldgs is facing a negative outlook because the investment case depends heavily on aggressive U.S. share gains and continued adoption of Motiva, yet the business still shows concentrated reliance on early-stage penetration, with U.S. revenue only recently reaching $24.7M, 2,000 accounts, and growth increasingly driven by utilization rather than broad-based demand. Even though the company is expected to generate $270M of revenue in FY26E with $21M of adjusted EBITDA, the path to $338M in FY27E and $414M in FY28E assumes sustained momentum in a highly competitive market, while outside the U.S. growth is modeled at only low single digits from $170M in FY26E to $188M in FY28E. The outlook is further pressured by meaningful execution risks cited in the source, including recession sensitivity, competition, unexpected complications in the treated population, funding needs, unsuccessful pipeline launches, tariffs, and intellectual property issues, all of which could undermine the lofty growth assumptions embedded in the model.